Skip to main content
Premium Trial:

Request an Annual Quote

Singular Genomics Systems Raises $258M in Upsized IPO

NEW YORK – Singular Genomics Systems went public on the Nasdaq on Thursday after the firm priced its initial public offering of approximately 11.7 million shares at $22 per share the previous day, for anticipated gross proceeds of about $258.1 million before underwriting discounts, commissions, and other expenses.

In a Wednesday filing with the US Securities and Exchange Commission, the San Diego-based sequencing technology firm added nearly 2 million more shares to the offering. Previously, it had targeted a $187 million IPO.

Shares began trading on Thursday on the Nasdaq and rose to $29.00 per share before closing up 17 percent at $25.72.

JP Morgan, Goldman Sachs, Bank of America, and Cowen acted as joint bookrunning managers for the offering and as representatives of the underwriters. UBS also acted as a bookrunning manager. The underwriters have a 30-day option to purchase up to 1.5 million shares.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.